Program
belantamab mafodotin
Also written as “Belantamab mafodotin”, “Belantamab Mafodotin” and “GSK2857916”.
Its studies are mostly in Multiple Myeloma · Amyloidosis, led by GlaxoSmithKline.
Furthest: phase 3, since Nov 11, 201925 company-led studies, 18 open or runningNext primary completion: Aug 3, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 2518 open or running | phase 3since Nov 11, 2019 | Feb 13, 2014 | Aug 3, 2028phase 2 · NCT05714839 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Feb 13, 2014.
- May 19, 20202 phase 1 studies in Multiple MyelomaNCT04398745, NCT04398680
- Jul 21, 2020Phase 3 study in Multiple MyelomaNCT04484623 · 302 enrolled · United States, Australia, Brazil and more
- Sep 8, 2020Phase 3 study in Multiple MyelomaNCT04549363 · 16 enrolled · United States
- Sep 22, 2021Phase 2 study in Multiple MyelomaNCT05064358 · 177 enrolled · United States, Argentina, Australia and more
- Jan 27, 2023Phase 2 study in Multiple MyelomaNCT05714839 · 123 planned · United States, Argentina, Australia and more
- Oct 22, 2024Phase 2 study in Multiple MyelomaNCT06655818 · 4 enrolled · France, Korea, Republic of
- Nov 6, 2024Phase 3 study in Multiple MyelomaNCT06679101 · 520 planned · United States, Argentina, Australia and more
- Mar 6, 20252 phase 3 studies in Multiple MyelomaNCT06868667, NCT06868654
- Apr 25, 2025Phase 3 study in Multiple MyelomaNCT06956170 · 21 enrolled · Japan
- Jul 22, 2025Phase 2 study in Multiple MyelomaNCT07084896 · 106 enrolled · United States, Australia, Canada and more
- Aug 25, 20252 phase 2 studies in Multiple MyelomaNCT07150104, NCT07150091
- Oct 13, 20253 phase 2 studiesNCT07217184, NCT07217119, NCT07224672
- May 20, 2026Phase 1 study in Multiple MyelomaNCT07609706 · 20 planned
- May 21, 2026Phase 2 study in Multiple MyelomaNCT07614360 · 150 planned
Ahead
- Aug 3, 2028Primary completion: phase 2 study in Multiple MyelomaNCT05714839
- Feb 28, 2029Primary completion: phase 2 study in Multiple MyelomaNCT07614360
- Apr 28, 2031Primary completion: phase 3 study in Multiple MyelomaNCT06679101
- Aug 22, 2031Primary completion: phase 1 study in Multiple MyelomaNCT07609706
TargetBeta
TNFRSF17 →read by rule
“An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrule | cartesian-therapeutics | phase 2 | 6 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07614360Multiple Myeloma | 2 | Not yet recruiting | Feb 28, 2029 | 150 |
| NCT07609706Multiple Myeloma | 1 | Not yet recruiting | Aug 22, 2031 | 20 |
| NCT07224672Amyloidosis · United States, Australia, United Kingdom | 2 | Recruiting | Jan 12, 2033 | 60 |
| NCT07217184Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Apr 17, 2025 | 30 |
| NCT07217119Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 25 |
| NCT07150104Multiple Myeloma · Brazil, Canada, France and more | 2 | Active, not recruiting | Apr 17, 2025 | 14 |
| NCT07150091Multiple Myeloma · United States, Brazil, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 20 |
| NCT07084896Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 106 |
| NCT06956170Multiple Myeloma · Japan | 3 | Active, not recruiting | May 27, 2024 | 21 |
| NCT06868667Multiple Myeloma · Japan | 3 | Active, not recruiting | Apr 3, 2024 | 24 |
| NCT06868654Multiple Myeloma · China | 3 | Active, not recruiting | Apr 3, 2024 | 72 |
| NCT06679101Multiple Myeloma · United States, Argentina, Australia and more | 3 | Recruiting | Apr 28, 2031 | 520 |
| NCT06655818Multiple Myeloma · France, Korea, Republic of | 2 | Terminated | Feb 14, 2024 | 4 |
| NCT05714839Multiple Myeloma · United States, Argentina, Australia and more | 2 | Recruiting | Aug 3, 2028 | 123 |
| NCT05064358Multiple Myeloma · United States, Argentina, Australia and more | 2 | Completed | Aug 19, 2024 | 177 |
| NCT04549363Multiple Myeloma · United States | 3 | Terminated | Nov 21, 2022 | 16 |
| NCT04484623Multiple Myeloma · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jan 29, 2024 | 302 |
| NCT04398745Multiple Myeloma · Greece, South Korea | 1 | Active, not recruiting | Apr 21, 2025 | 36 |
| NCT04398680Multiple Myeloma · United States, Greece, South Korea | 1 | Withdrawn | Nov 4, 2025 | 0 |
| NCT04246047Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Oct 2, 2023 | 494 |
| NCT04177823Multiple Myeloma · China | 1 | Completed | Dec 30, 2021 | 6 |
| NCT04162210Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 12, 2022 | 325 |
| NCT04091126Multiple Myeloma · United States, Australia, Canada and more | 1 | Active, not recruiting | Jun 2, 2025 | 118 |
| NCT03848845Multiple Myeloma · United States, Canada, Germany and more | 2 | Completed | Oct 18, 2021 | 41 |
| NCT02064387Multiple Myeloma · United States, Canada, United Kingdom | 1 | Completed | Aug 31, 2018 | 79 |
How it is read
Names in the registry
- “Belantamab mafodotin”, 22 entries
- “Belantamab Mafodotin”, 1 entry
- “belantamab mafodotin”, 1 entry
- “GSK2857916”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 24 studies
- Amyloidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.